Results 201 to 210 of about 178,943 (330)

Intracellular cholesterol transporters and modulation of hepatic lipid metabolism: implications for diabetic dyslipidaemia and steatosis [PDF]

, 2014
Caridis, Anna-Maria, Dolan, Sharron, Graham, Annette, Soffientini, Ugo   +3 more
core   +1 more source

Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients

, 2016
Meng Wang, James P. Corsetti, Scott McNitt, David Q. Rich, Charles E. Sparks, Arthur J. Moss, Wojciech Zaręba   +6 more
openalex   +2 more sources

Effects of Changes in Metabolic Syndrome Status on Cognitive Function: A 10‐Year Study in a Middle‐Aged Population

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The long‐term cumulative impact of metabolic syndrome (MS) on cognitive decline remains uncertain. This study investigated how changes in MS status over 10 years relate to cognition and whether sex modifies this relationship. A total of 766 participants (mean baseline age: 54 years) from the Kaohsiung Atherosclerosis Longitudinal Study were ...
Kelly Lim, Meng‐Ni Wu, Wei‐Chia Tsao, Wei‐Hao Lin, Suh‐Hang Hank Juo, Cheng‐Sheng Chen, Hsiu‐Fen Lin   +6 more
wiley   +1 more source

IMB2026791, a Xanthone, Stimulates Cholesterol Efflux by Increasing the Binding of Apolipoprotein A-I to ATP-Binding Cassette Transporter A1 [PDF]

, 2012
Jikai Liu, Zhongbing Zhang, Yanni Xu, Tingting Feng, Wei Jiang, Zhuorong Li, Bin Hong, Zijian Xie, Shuyi Si   +8 more
openalex   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, EarlyView.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study. [PDF]

Int J Gen Med
He X, Li F, Zhang J, Wen Z, Li Y, Gao W, Chen H, Yu Y, Zheng Y, Xie X.   +9 more
europepmc   +1 more source

Genome-wide search for QTLs for apolipoprotein A-I level in elderly Swedish DZ twins: evidence of female-specific locus on 15q11–13 [PDF]

, 2008
Patrik K. E. Magnusson, Marcus Boman, Ulf dé Fairé, Markus Perola, Leena Peltonen, Nancy L. Pedersen   +5 more
openalex   +1 more source

Changes in Plasma Sphingolipid Metabolites Following Roux‐En‐Y Gastric Bypass in Women With Obesity and Type 2 Diabetes: A Pilot Metabolomic Cohort Study

Lipids, EarlyView.
ABSTRACT Although sphingolipids are key players in lipotoxicity and metabolic diseases, their response to bariatric surgery and their relation to metabolic improvement remain unclear. This pilot study investigated plasma sphingolipid remodeling after Roux‐en‐Y gastric bypass (RYGB) and its associations with clinical and biochemical markers of ...
Gabriela de Oliveira Lemos, Raquel Susana Torrinhas, Natasha Mendonça Machado, Dan Linetzky Waitzberg   +3 more
wiley   +1 more source

Prediction of apolipoprotein A-I and high-density lipoprotein cholesterol in the neurological impairment and relapse of neuromyelitis optica spectrum disorder. [PDF]

Front Neurosci
Wang Y, Wang F, Huang T, Zeng Z, Jiao L, Sun H, Zhang X, Wang B, Liu R, Guo S.   +9 more
europepmc   +1 more source

The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?

, 2015
Sabrina Pagano, Hubert Gaertner, Fabrice Cerini, Tiphaine Mannic, Nathalie Satta, Priscila Camillo Teixeira, Paul Cutler, François Mach, Nicolas Vuilleumier, Oliver Hartley   +9 more
openalex   +2 more sources